None
Quote | OKYO Pharma Corp (OTCMKTS:EMMLF)
Last: | $0.0137 |
---|---|
Change Percent: | -169.34% |
Open: | $0.0369 |
Close: | $0.0137 |
High: | $0.0369 |
Low: | $0.0137 |
Volume: | 10,100 |
Last Trade Date Time: | 05/12/2023 03:00:00 am |
News | OKYO Pharma Corp (OTCMKTS:EMMLF)
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP. Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clini...
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the clos...
Message Board Posts | OKYO Pharma Corp (OTCMKTS:EMMLF)
Subject | By | Source | When |
---|---|---|---|
Stock_Tracker: Latest West African (EMMLF) Headlines The New York Society of Security Analysts' Conf | Stock_Tracker | investorshangout | 03/09/2014 9:55:43 PM |
chartguy89: EMMLF 0.141 Stock Charts $EMMLF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 6:42:43 AM |
chartguy89: EMMLF Stock Charts Last: -0.0184 Tuesday, February 25, 2014 at 10:31:21 PM $EMMLF | chartguy89 | investorshangout | 02/26/2014 3:31:33 AM |
News, Short Squeeze, Breakout and More Instantly...
OKYO Pharma Corp Company Name:
EMMLF Stock Symbol:
OTCMKTS Market:
OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP. Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clini...
LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the clos...
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED”), today announced the pric...